Abstract
As observed in the case of COVID-19, effective vaccines for an emerging pandemic tend to be in limited supply initially and must be allocated strategically. The allocation of vaccines can be modeled as a discrete optimization problem that prior research has shown to be computationally difficult (i.e., NP-hard) to solve even approximately.
Using a combination of theoretical and experimental results, we show that this hardness result may be circumvented. We present our results in the context of a metapopulation model, which views a population as composed of geographically dispersed heterogeneous subpopulations, with arbitrary travel patterns between them. In this setting, vaccine bundles are allocated at a subpopulation level, and so the vaccine allocation problem can be formulated as a problem of maximizing an integer lattice function 
subject to a budget constraint ∥x∥1 ≤ D. We consider a variety of simple, well-known greedy algorithms for this problem and show the effectiveness of these algorithms for three problem instances at different scales: New Hampshire (10 counties, population 1.4 million), Iowa (99 counties, population 3.2 million), and Texas (254 counties, population 30.03 million). We provide a theoretical explanation for this effectiveness by showing that the approximation factor of these algorithms depends on the submodularity ratio of objective function g, a measure of how distant g is from being submodular.
Author summary Strategic and timely allocation of vaccines is crucial in combating epidemic outbreaks. Developing strategies to allocate vaccines over sub-populations rather than to individuals leads to policy recommendations that are more feasible in practice. Despite this, vaccine allocation over sub-populations has only received limited research interest, and the associated computational challenges are relatively unknown. To address this gap, we study vaccine allocation problems over geographically distinct subpopulations in this paper. We formulate our problems to reduce either i) the total infections or ii) the sum of peak infections over meta-population disease models. We first demonstrate that these problems are computationally challenging even to approximate and then show that a family of simple, well-known greedy algorithms exhibit provable guarantees. We conduct realistic experiments on state-level mobility networks derived from real-world data in three states of distinct population levels: New Hampshire, Iowa, and Texas. Our results show that the greedy algorithms we consider are i) scalable and ii) outperform both state-of-the-art and natural baselines in a majority of settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this research was provided as part of the CDC MInD Healthcare group under cooperative agreement U01CK000594 and associated Covid19 supplemental funding. Authors BA and SVP were awarded the grant and all 4 authors were supported by the grant. URL: https://www.cdc.gov/hai/research/MIND-Healthcare.html Additional funding was provided by NSF Award Number 1955939. Author SVP was awarded this grant and authors JK and SVP were supported by the grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study will only use openly (to academics in one case) available data. The first source is a synthetic population derived from the 2010 United States Census we refer to as the "FRED" dataset (https://fred.publichealth.pitt.edu/syn_pops), which is freely available on the open internet. We also use a human mobility dataset we refer to as "SafeGraph" (https://www.safegraph.com/). Limited samples of this dataset are available, which we used in a county-aggregated form.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* sriram-pemmaraju{at}uiowa.edu
Data Availability
Our experimental framework, all data processing and algorithm code, and output analysis are available on Zenodo at link https://doi.org/10.5281/zenodo.13882892
